Patents by Inventor Stephen M. Boue

Stephen M. Boue has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 9669004
    Abstract: Provided are compositions for treatment of cancers, including breast cancer, comprising at least one novel daidzein analog, as well as methods of using the same for preventing or treating cancer or tumor growth.
    Type: Grant
    Filed: January 15, 2015
    Date of Patent: June 6, 2017
    Assignees: The Administrators of the Tulane Educational Fund, United States Department of Agriculture, Xavier University of Louisiana
    Inventors: Guangdi Wang, Matthew E. Burow, Stephen M. Boue, Thomas E. Wiese, Quan Jiang
  • Publication number: 20170065554
    Abstract: The present disclosure encompasses, among other things, compositions and methods of enhancing glyceollin content of soybean tissue as well as methods of large-scale production of soybean tissues comprising elevated glyceollin content. The present disclosure further encompasses administration of food products comprising glyceollins in the treatment or prevention (i.e., delay of onset) of overweight, obesity, prediabetes, diabetes, IBD, and gastrointestinal dysbiosis.
    Type: Application
    Filed: February 20, 2015
    Publication date: March 9, 2017
    Inventors: Mark L. HEIMAN, Stephen M. BOUE
  • Patent number: 9227898
    Abstract: It has been discovered that irradiating the cut side of sugarcane billets, preferably 2-50 mm, with UVB or UVC light or combinations thereof initiates stilbene production, particularly resveratrol and piceatannol. In an embodiment the cut sides of sugarcane billets of a predetermined thickness are irradiated with Ultraviolet-C or Ultraviolet-B light or combinations thereof at an intensity and for a duration of time sufficient to produce a significant increase in a level of one or more stilbenes in the irradiated billets compared to a level of stilbenes in billets that are not irradiated; and the irradiated sugarcane billets are maintained for at least about three days up to about 20 days, to optimize stilbene levels.
    Type: Grant
    Filed: January 28, 2013
    Date of Patent: January 5, 2016
    Assignee: The Administrators of the Tulane Edcational Fund
    Inventors: Stephen M. Boue, Matthew E. Burow, Deepak Bhatnagar
  • Publication number: 20150148409
    Abstract: Provided are compositions for treatment of cancers, including breast cancer, comprising at least one novel daidzein analog, as well as methods of using the same for preventing or treating cancer or tumor growth.
    Type: Application
    Filed: January 15, 2015
    Publication date: May 28, 2015
    Inventors: Guangdi WANG, Matthew E. BUROW, Stephen M. BOUE, Thomas E. WIESE, Quan JIANG
  • Patent number: 8987198
    Abstract: Disclosed are methods of modulating the expression of genes linked to adipocytokine signaling, carbohydrate metabolism, fatty acid metabolism, arachidonic acid metabolism, PPAR signaling, insulin signaling, lipid metabolism, extracellular matrix (ECM)-receptor interaction, or combinations thereof, methods of treating hyperlipidemia, obesity, excessive cholesterol, cardiovascular disease, liver disease, diabetes, or combinations thereof, and methods of stimulating glucose uptake in an animal in need thereof, comprising administering a composition comprising at least one isolated glyceollin to said animal.
    Type: Grant
    Filed: December 22, 2010
    Date of Patent: March 24, 2015
    Assignees: The Administrators of the Tulane Educational Fund, The United States Department of Agriculture, Wake Forest University Health Sciences, Nume Health, LLC
    Inventors: Matthew E. Burow, Stephen M. Boue, Thomas T. Y. Wang, Deepak Bhatnagar, Charles E. Wood, Mark L. Helman
  • Patent number: 8962679
    Abstract: Provided are compositions for treatment of cancers, including breast cancer, comprising at least one novel daidzein analog, as well as methods of using the same for preventing or treating cancer or tumor growth.
    Type: Grant
    Filed: July 8, 2011
    Date of Patent: February 24, 2015
    Assignees: The Administrators of the Tulane Educational Fund, Xavier University of Louisiana
    Inventors: Guangdi Wang, Matthew E. Burow, Stephen M. Boue, Thomas E. Wiese, Quan Jiang
  • Publication number: 20150005533
    Abstract: It has been discovered that irradiating the cut side of sugarcane billets, preferably 2-50 mm, with UVB or UVC light or combinations thereof initiates stilbene production, particularly resveratrol and piceatannol. In an embodiment the cut sides of sugarcane billets of a predetermined thickness are irradiated with Ultraviolet-C or Ultraviolet-B light or combinations thereof at an intensity and for a duration of time sufficient to produce a significant increase in a level of one or more stilbenes in the irradiated billets compared to a level of stilbenes in billets that are not irradiated; and the the irradiated sugarcane billets are maintained for at least about three days up to about 20 days, to optimize stilbene levels.
    Type: Application
    Filed: January 28, 2013
    Publication date: January 1, 2015
    Applicant: THE ADMINISTRATORS OF THE TULANE EDCATIONAL FUND
    Inventors: Stephen M. Boue, Matthew E. Burow, Deepak Bhatnagar
  • Patent number: 8563599
    Abstract: Two distinct methods are disclosed and claimed for synthesizing glyceollin I plus glyceollin II as a mixture and as their pure forms. Stereochemical isomers and various synthetic intermediates are also synthesized and claimed for their novel compositions of matter. All compounds and their mixtures are claimed for use in formulations that are useful to treat or prevent cancer, or that have utility as selective estrogen receptor modulators, such formulations including enhanced or medical foods, dietary supplements and ethical pharmaceutical agents.
    Type: Grant
    Filed: March 3, 2009
    Date of Patent: October 22, 2013
    Assignees: The United States of America, represented by the Secretary of Agriculture, Xavier University of Louisiana, University of Toledo
    Inventors: Paul W. Erhardt, Rahul Khupse, Jefferey G. Sarver, Thomas E. Cleveland, Stephen M. Boue, Thomas E. Wiese, Matthew E. Burow, John A. McLachlan
  • Patent number: 8497249
    Abstract: CAY-1 is a fungicidal saponin from the cayenne pepper (Capsicum frutescens) fruit. The saponins 1081 and 919, closely elute with, and are close structural relatives of, CAY-1. Saponin 1081 is poorly antifungal while 919 has no antifungal properties. Nongerminated and germinating conidia of Aspergilus flavus, A. fumigatus, A. niger, Fusarium oxysporum, F. solani, and F. verticilioides were tested against pure CAY-1 and CAY-1:1081:919 at ratios of 8:1:1, 6:2:2 and 4:3:3 and efficacy was determined after various incubation times. Pure CAY-1 and all saponin mixtures were significantly (p<0.001) lethal to the germinating conidia of A. flavus, A. niger, and F. solani. All saponin mixtures were equal or superior to pure CAY-1 in antifungal properties. Mixtures of the naturally occurring inactive or poorly fungicidal saponins with reduced levels of CAY-1 display superior fungicidal properties when compared to pure CAY-1 at the same dose levels.
    Type: Grant
    Filed: October 2, 2009
    Date of Patent: July 30, 2013
    Assignee: The United States of America, as represented by the Secretary of Agriculture
    Inventors: Anthony J. De Lucca, Stephen M. Boue
  • Publication number: 20130184475
    Abstract: Provided are compositions for treatment of cancers, including breast cancer, comprising at least one novel daidzein analog, as well as methods of using the same for preventing or treating cancer or tumor growth.
    Type: Application
    Filed: July 8, 2011
    Publication date: July 18, 2013
    Applicants: THE ADMINISTRATORS OF THE TULANE EDUCATIONAL FUND, XAVIER UNIVERSITY OF LOUISIANNA, UNITED STATES DEPARTMENT OF AGRICULTURE
    Inventors: Guangdi Wang, Matthew E. Burow, Stephen M. Boue, Thomas E. Wiese, Quan Jiang
  • Publication number: 20130041022
    Abstract: The present disclosure demonstrates the molecular effects of glyceollins on human prostate cancer cell LNCaP to further elucidate its potential effects on prostate cancer prevention. The glyceollins inhibited LNCaP cell growth similar to that of the soy isoflavone genistein. The growth inhibitory effects of the glyceollins appeared to be due to an inhibition on G1/S progression and correlated with an up-regulation of cyclin-dependent kinase inhibitor A1 and B1 mRNA and protein levels. By contrast, genistein only up-regulates cyclin-dependent kinase inhibitor A1. In addition, glyceollin treatments led to down-regulated mRNA levels for androgen responsive genes. In contrast to genistein, this effect of glyceollins on androgen responsive genes appeared to be mediated through modulation of an estrogen- but not androgen-mediated pathway.
    Type: Application
    Filed: December 22, 2009
    Publication date: February 14, 2013
    Applicants: UNITED STATES DEPARTMENT OF AGRICULTURE, THE ADMINISTRATORS OF THE TULANE EDUCATIONAL FUND
    Inventors: Thomas E. Cleveland, Stephen M. Boue, Matthew E. Burow, Thomas T.Y. Wang
  • Patent number: 8323706
    Abstract: The flavonoid family of phytochemicals, particularly those derived from soy, has received attention regarding their hormonal activity and their effects on human health and disease. The types and amounts of these compounds in soy and other plants are controlled by both constitutive expression and stress-induced biosynthesis. The health benefits of soy may therefore be dependent upon the amounts of the various hormonally active phytochemicals present. We have identified increased biosynthesis of the isoflavonoid phytoalexin compounds, Glyceollins I, II and III, in soy plants grown under stressed conditions (elicited soy), which exhibit marked anti-estrogenic effects on ER function.
    Type: Grant
    Filed: April 11, 2008
    Date of Patent: December 4, 2012
    Assignees: The United States of America, as represented by the Secretary of Agriculture, Tulane Educational Fund
    Inventors: Thomas E. Cleveland, Stephen M. Boue, Matthew E. Burow, John A. McLachlan
  • Publication number: 20110237505
    Abstract: Disclosed are methods of modulating the expression of genes linked to adipocytokine signaling, carbohydrate metabolism, fatty acid metabolism, arachidonic acid metabolism, PPAR signaling, insulin signaling, lipid metabolism, extracellular matrix (ECM)-receptor interaction, or combinations thereof, methods of treating hyperlipidemia, obesity, excessive cholesterol, cardiovascular disease, liver disease, diabetes, or combinations thereof, and methods of stimulating glucose uptake in an animal in need thereof, comprising administering a composition comprising at least one isolated glyceollin to said animal.
    Type: Application
    Filed: December 22, 2010
    Publication date: September 29, 2011
    Applicant: THE ADMINISTRATORS OF THE TULANE EDUCATIONAL FUND
    Inventors: Matthew E. BUROW, Stephen M. BOUE, Thomas T.Y. WANG, Deepak BHATNAGAR, Charles E. WOOD, Mark A. HEIMAN
  • Publication number: 20110144195
    Abstract: Two distinct methods are disclosed and claimed for synthesizing glyceollin I plus glyceollin II as a mixture and as their pure forms. Stereochemical isomers and various synthetic intermediates are also synthesized and claimed for their novel compositions of matter. All compounds and their mixtures are claimed for use in formulations that are useful to treat or prevent cancer, or that have utility as selective estrogen receptor modulators, such formulations including enhanced or medical foods, dietary supplements and ethical pharmaceutical agents.
    Type: Application
    Filed: March 3, 2009
    Publication date: June 16, 2011
    Inventors: Paul W. Erhardt, Rahul Khupse, Jeffrerey G. Sarver, Thomas E. Cleveland, Stephen M. Boue, Thomas E. Wiese, Matthew E. Burow, John A. McClachlan
  • Publication number: 20080200537
    Abstract: The flavonoid family of phytochemicals, particularly those derived from soy, has received attention regarding their hormonal activity and their effects on human health and disease. The types and amounts of these compounds in soy and other plants are controlled by both constitutive expression and stress-induced biosynthesis. The health benefits of soy may therefore be dependent upon the amounts of the various hormonally active phytochemicals present. We have identified increased biosynthesis of the isoflavonoid phytoalexin compounds, Glyceollins I, II and III, in soy plants grown under stressed conditions (elicited soy), which exhibit marked anti-estrogenic effects on ER function.
    Type: Application
    Filed: April 11, 2008
    Publication date: August 21, 2008
    Inventors: Thomas E. Cleveland, Stephen M. Boue, Matthew E. Burow, John A. McLachlan